Article Per Year (5 Year)
p-Index From 2019 - 2024
0.408
P-Index
This Author published in this journals
All Journal Health Information : Jurnal Penelitian
Ilma Tria Nursyifa
Universitas Tarumanagara
Dentistry Health Professions Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Health Information : Jurnal Penelitian

 1 
Penggunaan Eculizumab sebagai Pilihan Terapi pada Pasien HUS dengan Transplantasi Ginjal Ilma Tria Nursyifa; Puspa Dewanti; Inggerit Inggerit; Johansen Johansen; Sylvia Regina
Health Information : Jurnal Penelitian Vol 15 No 2 (2023): Suplemen
Publisher : Poltekkes Kemenkes Kendari

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Hemolytic Uremic Syndrome (HUS) is a form of thrombotic microangiopathy characterized by thrombocytopenia, microangiopathic hemolytic anemia and acute renal failure, occur in both children and adults. Eculizumab is a chimeric IgG2/4 monoclonal antibody that pairs with complement protein C5 and is used to treat or prevent relapse of HUS after kidney transplantation. Purpose: This article aims to determine the use of eculizumab as a therapeutic option in HUS patients with kidney transplants and explaining both the clinical effect and the method of administration. Method: Literature review from two databases, namely Google Scholar and PubMed, which were published within the last 5 years, from 2018-2023. Results: There were 11 literatures proving that eculizumab can be considered as a therapeutic option in HUS patients with kidney transplantation. Eculizumab can reduce the risk of recurrence or the emergence of HUS after kidney transplantation. Although most of the side effects of eculizumab are not serious, meningitis and death cannot be ruled out. So guidelines for the use of eculizumab are needed based on larger data to reduce the risk of infection and cost lost.
Pemeriksaan Biomarker Pada Pasien Dengan Dermatitis Atopik : Sebuah Review Jhodi Rent Geopal; Erin Elvira; Claudia Claudia; Ilma Tria Nursyifa; Celine Celine
Health Information : Jurnal Penelitian Vol 15 No 2 (2023): Suplemen
Publisher : Poltekkes Kemenkes Kendari

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by acute eczema or chronic lichenified lesions with heterogeneity. This skin disease affects almost 10-20% of people worldwide. The course involves chronic relapses that significantly reduce the patient's quality of life. Biomarkers have always existed for various purposes in medicine, especially as a diagnostic tool. However, there is currently a shortage of suitable biomarkers for atopic dermatitis, largely due to difficulties in sampling. Purpose: To find out the latest biomarkers that can be used in patients with atopic dermatitis. Method: Literature review are taken from PubMed and Google Scholar databases published within the last 5 years, from 2018-2022. Results: Based on the literature, there are several biomarkers that can be used for patients with atopic dermatitis including TARC or CCL17, CCL27, phytosphingosine CD300a, Interleukin-1 family (IL-18, IL1?, CXCL8), adipokines, FABP5, filaggrin. Conclusion: From the literature it was found that there are several current biomarkers for patients with atopic dermatitis that can be used as markers of clinical disease severity and monitoring of disease progression, as prognostic markers, screening and diagnosis tools.
Co-Authors Celine Celine Claudia Claudia Erin Elvira Inggerit Inggerit Jhodi Rent Geopal Johansen Johansen Puspa Dewanti Sylvia Regina